Results 11 to 20 of about 25,328 (173)

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Chronic Dis Transl Med
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Rinaldi I, Yonatan ER, Esterita T.
europepmc   +2 more sources

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN. [PDF]

Cancer Sci
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Mitsudomi T, Heymach JV, Horio Y, Tanaka F, Tanaka H, Kuyama S, Okada M, Toyooka S, Watanabe Y, Reck M, Harpole D, Taube JM, Olivo Y, Xiong H, Fouad TM, Chen A, Akamatsu H.   +16 more
europepmc   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Unresectable stage III non-small cell lung cancer: could durvalumab be safe and effective in real-life clinical scenarios? Results of a single-center experience

Frontiers in Oncology, 2023
IntroductionThe standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by consolidation durvalumab as shown in the PACIFIC trial.
Paolo Borghetti, Giulia Volpi, Giorgio Facheris, Gianluca Cossali, Eneida Mataj, Salvatore La Mattina, Navdeep Singh, Jessica Imbrescia, Marco Lorenzo Bonù, Davide Tomasini, Paola Vitali, Diana Greco, Michela Bezzi, Flavia Melotti, Mauro Benvenuti, Andrea Borghesi, Salvatore Grisanti, Michela Buglione di Monale e Bastia   +17 more
doaj   +1 more source

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

Cancer Medicine, 2020
Introduction Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen.
Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy   +13 more
doaj   +1 more source

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

Thoracic Cancer, 2023
Background Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial.
Emma Boys, Bo Gao, Rina Hui, Inês daSilva, Eric Hau, Harriet Gee, Adnan Nagrial   +6 more
doaj   +1 more source

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC

JTO Clinical and Research Reports, 2023
Introduction: Durvalumab maintenance therapy after definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III NSCLC. Although severe treatment-related lymphopenia (TRL) during CRT may impair the efficacy of subsequent ...
Tomoki Kuge, MD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Masaki Kanazu, MD, Yuhei Kinehara, MD, PhD, Tsunehiro Tanaka, MD, Osamu Morimura, MD, PhD, Yoshihiko Taniguchi, MD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Kazuhiko Hayashi, MD, PhD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD   +14 more
doaj   +1 more source

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

BMC Cancer, 2022
Background Investigating dynamic changes in blood-parameters and weight in patients with locally advanced non-small cell lung cancer (NSCLC) receiving durvalumab maintenance therapy after chemoradiotherapy (cCRT).
J. Guggenberger, S. Kenndoff, J. Taugner, L. Käsmann, B. Flörsch, C. Belka, C. Eze, F. Manapov   +7 more
doaj   +1 more source

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

Frontiers in Public Health, 2023
ObjectiveThe TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option.
Zhuo-miao Ye, Zhe Xu, Huan Li, Qian Li
doaj   +1 more source

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

JTO Clinical and Research Reports, 2022
Introduction: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients.
Wang Jing, MD, Ting Xu, PhD, Lirong Wu, MD, Pablo B. Lopez, MD, Clemens Grassberger, PhD, Susannah G. Ellsworth, MD, Radhe Mohan, PhD, Brian P. Hobbs, PhD, George R. Blumenschein, MD, Janet Tu, MD, Mehmet Altan, MD, Percy Lee, MD, Zhongxing Liao, MD, Steven H. Lin, MD, PhD   +13 more
doaj   +1 more source